Inovio's Covid 19 Vaccine Demonstrates long-term protection in both the earlier strain AND the NEW more dangerous mutant !

Stock Talk

News from Inovio (INO):

- INO-4800 showed durable antibody and T cell responses in rhesus macaques for 4 months
- INO-4800 is the only vaccine to demonstrate long-term protection in non-human primates challenged with SARS-CoV-2 virus 13 weeks from vaccination
- Memory T and B cell responses resulted in reduced viral loads and faster viral clearance in macaques' lungs and nasal passages
- INO-4800 vaccination generated antibodies neutralizing both the earlier strain of virus as well as the mutant variant (D614G) that has emerged with greater infectivity, and now accounts for >80% of newly circulating virus
- No antibody-dependent enhanced disease events were reported

http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIOs-COVID-19-DNA-Vaccine-INO-4800-Provides-Protection-with-Memory-Immune-Responses-In-Non-Human-Primates-Challenged-with-SARS-CoV-2-Virus/default.aspx

_
Commentary:

Sure seems like the dots 
are connecting to success of
INO-4800 against Covid 19.


_ 

ALL in my humble opinion, scroll down and read more.. 

This site does NOT make Buy / Sell recommendations.
___